BOCH
IMVT icon

Blue Owl Capital Holdings’s Immunovant IMVT Stock Holding History

Blue Owl Capital Holdings’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80,000
Closed -$2.28M – 96
2024
Q3 		$2.28M Hold
80,000
– – 0.44% 38
2024
Q2 		$2.11M Sell
80,000
-20,000
-20% -$569K 0.59% 30
2024
Q1 		$3.23M Buy
100,000
+40,000
+67% +$1.46M 0.65% 30
2023
Q4 		$2.53M Buy
+60,000
New +$2.21M 0.6% 28

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Blue Owl Capital Holdings's IMVT Position: Q4 2024 in Review

Blue Owl Capital Holdings sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 80,000 shares — an estimated $2.28M sold.

Blue Owl Capital Holdings first reported a position in IMVT in Q4 2023 and held it in 4 quarters. The position peaked at $3.23M in Q1 2024. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • Blue Owl Capital Holdings reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • Blue Owl Capital Holdings sold 80,000 Immunovant shares in Q4 2024, an estimated $2.28M.
  • Blue Owl Capital Holdings first reported a position in Immunovant in Q4 2023 and held it in 4 quarters.
  • Blue Owl Capital Holdings's Immunovant position peaked at $3.23M in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Blue Owl Capital Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.